Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough
Previously Announced Statistically Significant Interim Analysis Established Proof of Concept Efficacy and Safety Data Expected on the Full Set of Subjects in Third Quarter 2022 NEW HAVEN, Conn.,... | March 15, 2022
Source: marketscreener.com